

4-32852A

-21-

CLAIMS

1. Process for modifying the crystal habit of an acicular drug substance comprising suspending said crystalline drug substance in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.
- 5 2. Process for recrystallising an acicular drug substance comprising suspending said crystals in a solvent system having an effect on the crystal habit and subjecting said suspension to a temperature oscillation.
3. Process according to claim 1 or 2 wherein the crystal habit is modified in that the mean aspect ratio of the processed crystals is smaller than about 10:1.
- 10 4. Process according to any one of claims 1 to 3 wherein the drug substance after temperature oscillation has a bulk density of about above 200 kg/m<sup>3</sup>.
5. Process according to any preceding claim wherein the temperature oscillation is in form of a zig-zag curve.
- 15 6. A process according to any one of claims 1 to 5 for producing crystals having a mean aspect ratio of the processed crystals smaller than about 10:1 or a bulk density of about 200 kg/m<sup>3</sup>.
7. Crystals of an acicular drug substance with an aspect ratio of about 10:1 to 1:1 and/or a bulk density of above about 200 kg/m<sup>3</sup>.
- 20 8. Crystals according to claim 7 wherein the acicular drug substance is mycophenolic acid or a mycophenolate salt.
9. A pharmaceutical composition, e.g. in the form of tablets, comprising crystals of claim 7 or 8 in association with a pharmaceutically acceptable carrier.
10. Crystals of claim 8 for use as a pharmaceutical.
- 25 11. A crystal modification of mycophenolic acid or mycophenolate sodium having one of the following characteristic crystal structures, determined by means of an X-ray single crystal analysis, or having an X-ray powder diffraction pattern as defined below:
  - a) mycophenolate sodium anhydrate, modification A;

crystal system:	monoclinic
space group:	P2 <sub>1</sub> /c
a:	16.544(4)
- 30

4-32852A

-22-

b: 4.477(1)  
c: 21.993(3)  
 $\beta$ : 92.14(1) $^\circ$   
V: 1627.8(6)  
5 Z: 4  
cal. Density: 1.397 g/cm<sup>3</sup>

b) mycophenolate sodium hydrate;

having an X-ray powder diffraction pattern with characteristic signals  
substantially the same as those shown in Figure 2;

10 c) hemisalt of mycophenolate sodium anhydrate;

crystal system: triclinic  
space group: P-1  
a: 11.172(6)  
b: 12.020(6)  
15 c: 13.441(2)  
 $\alpha$ : 73.09(7) $^\circ$   
 $\beta$ : 71.79(6) $^\circ$   
 $\gamma$ : 84.63(6) $^\circ$   
V: 1641(2)  
20 Z: 2

d) mycophenolate sodium methanol solvate;

crystal system: triclinic  
space group: P-1  
a: 7.761  
25 b: 9.588  
c: 14.094  
 $\alpha$ : 109.96 $^\circ$   
 $\beta$ : 95.99 $^\circ$   
 $\gamma$ : 83.05 $^\circ$   
30 V: 976.3  
Z: 2

e) mycophenolate sodium methanol solvate II;

crystal system: triclinic  
space group: P-1

4-32852A

-23-

a: 9.179  
 b: 10.724  
 c: 12.098  
 $\alpha$ : 113.27 °  
 5  $\beta$ : 101.76 °  
 $\gamma$ : 104.44 °  
 V 996.4  
 Z 2

f) mycophenolate disodium salt, monohydrate;

10 having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 6;

g) mycophenolate disodium salt, pentahydrate;

crystal system: monoclinic

space group:  $P 2_1/c$ ,

15 a: 14.495  
 b: 17.613  
 c: 8.401  
 $\beta$ : 97.15 °  
 V 2128  
 20 Z 4

h) mycophenolic acid;

crystal system: triclinic

space group:  $P -1$

25 a: 7.342  
 b: 9.552  
 c: 11.643  
 $\alpha$ : 102.70 °  
 $\beta$ : 90.89 °  
 $\gamma$ : 90.74 °  
 30 V 796.3  
 Z 2

i) mycophenolate sodium hydrate form B;

having an X-ray powder diffraction pattern with characteristic signals substantially the same as those shown in Figure 10;

4-32852A

-24-

- j) mycophenolate sodium hydrate form C;  
having an X-ray powder diffraction pattern with characteristic signals  
substantially the same as those shown in Figure 12.